Systemic HypertensionSystemic HypertensionСистемные гипертензии2075-082X2542-2189Intermedservice Ltd2895610.26442/SG28956ArticlesСтатьиResearch ArticleTorasemide: additional benefits for postmenopausal women with arterial hypertensionТорасемид: дополнительные преимущества применения при артериальной гипертензии у женщин в постменопаузеTkachevaO NТкачеваОльга Николаевна

д-р мед. наук, проф., первый заместитель директора по научной и лечебной работе

RunikhinaN KРунихинаНадежда Константиновна

д-р. мед. наук, проф., руководитель терапевтического отделения

SharashkinaN VШарашкинаНаталья Викторовна

канд. мед. наук, врач терапевтического отделени

ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава РФ, МоскваФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава РФ, Москва15062013102VOL 10, NO2 (2013)ТОМ 10, №2 (2013)91309042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://journals.eco-vector.com/2075-082X/article/view/28956

Effective and safe diuretic torasemide has additional effects of renin-angiotensin-aldosterone system blockage. Torasemide can be used as monotherapy or combined with other antihypertensives. In low doses torasemide produces pronounced antihypertensive effect without augmentation of excretion of potassium and water with urine. Long-term administration of torasemide was not associated with significant effects on lipid, purine, carbohydrate, or electrolyte metabolism parameters. Torasemide particularly effective in postmenopausal women, as these women are more likely formed low-renin hypertension. Therefore, torasemide can be used more widely in modern clinical practice.

Эффективный и безопасный петлевой диуретик торасемид в отличие от других петлевых диуретиков имеет дополнительные эффекты, связанные с одновременной блокадой ренин-ангиотензин-альдостероновой системы. Торасемид используется у больных артериальной гипертензией как в виде монотерапии, так и в комбинации с другими антигипертензивными средствами. В низких дозах торасемид оказывает длительное антигипертензивное действие, незначительно влияя на содержание калия в крови и показатели пуринового, углеводного и липидного метаболизма. Благодаря этому он может использоваться для длительного лечения артериальной гипертензии. Торасемид особенно эффективен у женщин в период постменопаузы, так как у этих женщин чаще формируется низкорениновая объемозависимая артериальная гипертензия. Таким образом, торасемид может быть использован для длительной антигипертензивной терапии у женщин в постменопаузе.

arterial hypertensiontorasemidethiazide diureticswomenpostmenopauseартериальная гипертензияторасемидтиазидные диуретикиженщиныпостменопаузаVasan R.S., Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle - aged women and men: the Framingham Heart Study. JAMA 2002; 287: 1003–10.Navar L.G., Harrison-Bernard L.M., Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002; 39 (2 Pt 2): 316–22.Thethi T, Kamiyama M, Kobori H. The link between the renin - angiotensin - aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 2012; 14 (2): 160–9.Weinberger M.H. Pathogenesis of salt sensitivity of blood pressure. Curr Hypertens Rep 2006; 8: 166–70.Schulman I.H., Aranda P, Raij L et al. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006; 47: 1168–74.Schulman I.H., Raij L. Salt sensitivity and hypertension after menopause: role of nitric oxide and angiotensin II. Am J Nephrol 2006; 26: 170–80.Grzegorczyk K, Krajewska M, Weyde W et al. Gender and kidney diseases: the clinical importance and mechanisms of modifying effects. Postepy Hig Med Dosw (Online) 2011; 65: 849–57.Boschitsch E, Mayerhofer S, Magometschnigg D. Hypertension in women: the role of progesterone and aldosterone. Climacteric 2010; 13: 307–13.Rossi G.P., Pessina A.C., Heagerthy A.M. Primary aldosteronism an updateon screening diagnosis and treatment. J Hypertens 2008; 26: 613–21.Joffe H.V., Alder K.A. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005; 10: 31–7.Schlaich M.P., Schobel H.P., Hilgers K, Schmieder R.E. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 2000; 85: 1199–206. Freel E.M., Connell J.M. Mechanisms of hypertension: the expanding role of aldosterone. J Am Soc Nephrol 2004; 15: 1993–2001.Rahmouni K, Correia M.L.G, Haynes W.G., Mark A.L. Obesity - associated hypertension. New insights into mechanisms. Hypertension 2005; 45: 9–14.Brilla C.G., Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120 (6): 893–901.Calhoun D.A. Aldosterone and cardiovascular disease: smoke and fire. Circulation 2006; 114: 2572–4.Christine Jellis. J Am Coll Cardiol 2010; 56 (2).Stas S, Whaley-Connell A, Habibi J et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin - angiotensin - aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007; 148 (8): 3773–80.Lastra G, Whaley-Connell A, Manrique C et al. Low - dose spironolactone reduces reactive oxygen species generation and improves insulin - stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008; 295 (1): E110–6.Bochud M, Nussberger J, Bovet P et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006; 48 (2): 239–45.Fujita T. Mineralocorticoid receptors, salt - sensitive hypertension and metabolic syndrome. Hypertension 2010; 55 (4): 813–8.Zannad F, Alla F, Dousset B et al. Limitation of excessive exracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insight from the randomized aldactone evaluation study (RALES). Circulation 2000; 102: 2700–6.Taddei S, Virdis A, Ghiadoni L et al. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62: 265–84.Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens (Suppl.) 2006; 24: S39–S43. Rizzoni D, Porteri E, De Ciuceis C et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin - dependent diabetes mellitus. Hypertension 2005; 45: 659–65.Rossi R, Nuzzo A, Iaccarino D et al. Effects of antihypertensive treatment on endothelial function in postmenopausal hypertensive women. A significant role for aldosterone inhibition. J Renin - Angiotensin - Aldosterone System 2011; 12: 446.Cachofeiro V, Miana M, de Las Heras N et al. Aldosterone and the vascular system. J Steroid Biochem Mol Biol 2008; 109: 331–5.Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831–8.Zillich A.J., Garg J, Basu S et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48 (2): 219–24.Fortuño A, Muñiz P, Ravassa S et al. Torasemide inhibits angiotensin II - induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension 1999; 34 (1):138–43.Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs Today 1994; 8: 1–28.López B. J Am Coll Cardiol 2004; 43 (11): 2028–35.Di Nicolantonio J.J. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol 2012; 8 (5): 707–28.Kasama S, Toyama T, Hatori T et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 2006; 92 (10): 1434–40.Cosin J, Diez J. On behalf of the TORIC investigators. Eur J Heart Fail 2002; 4: 507–13.Hermida R.C., Ayala D.E., Mojón A et al. Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int 2008; 25 (6): 950–70.Karagueuzian H.S. Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy? Am J Cardiovasc Dis 2011; 1 (2): 101–9.Werner U, Werner D, Heinbüchner S et al. Gender is an important determinant of the disposition of the loop diuretic torasemide. J Clin Pharmacol 2010; 50 (2): 160–8.